Centro de Atención e Investigación Médica

What Centro de Atención e Investigación Médica does

CAIMED is a privately held clinical research organization (CRO) headquartered in Chía (with principal operations in Bogotá), Colombia, founded in 2007 by Dr. Humberto Reynales. It operates 10 research centers across Colombia (Chía, Bogotá, Acacías, Aguazul, Yopal, Girardot), Puerto Rico, Dominican Republic, Mexico, and the United States (Florida and a joint Brownsville, TX center), supported by a strategic alliance with PanAmerican Clinical Research that brings the combined network to 12 trial sites. The company's core offering is sponsored clinical trial execution — primarily vaccine intervention studies, with secondary work in chronic disease pharmaceuticals, infectious diseases, special populations, and bioequivalence/bioavailability studies conducted at its Chía site — and it has run 87+ trials enrolling over 19,000 participants.

CAIMED runs on its proprietary MetricsMed electronic clinical research platform, which is validated and compliant with FDA Part 11 (Electronic Records and Electronic Signatures), enabling full digital data capture, traceability, and remote monitoring across sites. The technology stack is supported by an ecosystem of partners: Epicontact for call center/patient communication, Coltrials for monitoring and quality assurance, and Corporación Salud for research training. CAIMED also markets consumer-facing digital tools — the Preventiva vaccination scheduling platform, the Escuela de Pacientes cardiovascular education platform, and the Termómetro Cardiovascular screening tool — which extend the brand beyond sponsor work into recurring B2C engagement.

Revenue is generated through professional services contracts with pharmaceutical sponsors (per-study fees for trial conduct, recruitment, data, and regulatory compliance), direct B2C vaccination services (PAI and complementary vaccines), corporate vaccination programs, bioequivalence study fees, and Ethics Committee review services sold to other research centers. Go-to-market combines direct enterprise field sales to pharma sponsors with channel-based volunteer recruitment through its own website, social media, traditional Colombian media appearances, and community outreach. Anchor sponsor relationships include Sanofi Pasteur and CureVac AG (with Bayer as partner) for Phase IIb/III COVID-19 vaccine trials, and CAIMED also participated in the WHO Solidarity trial. The company holds ISO 9001 certification and operates under INVIMA approvals for trial conduct in Colombia.

Name

Centro de Atención e Investigación Médica

Legal name

CAIMED S.A.S.

Website

https://caimed.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

CAIMED is a Colombia-based clinical research organization operating 10 research centers across Latin America and the US, conducting vaccine, pharmaceutical, infectious disease, and bioequivalence clinical trials for pharma sponsors, complemented by B2C vaccination services.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Other Scientific and Technical Consulting Services (541690), Medical and Diagnostic Laboratories (62151)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM), Public & Private Vaccine Provider Networks (Clinics/Pharmacies/Physicians) (HLAJAHAB), Immunization & Vaccination Programs Administration (BPAIAJAD)

Keywords

• Clinical research services
• Vaccine clinical trials
• Bioequivalence studies
• Preventive medicine services
• Pharmaceutical clinical studies

Headquarters

HQ city

Bogotá

HQ country

Colombia

HQ region

Latin America

Offices11 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Contract Research: CAIMED conducts sponsored clinical trials for pharmaceutical companies (vaccines, drugs, cosmetics) and receives compensation for study conduct, patient recruitment, data collection, and regulatory compliance services.
2. Vaccination Services: Direct vaccination services to individuals (PAI and complementary vaccines) and corporate clients. Includes preventive medicine and therapeutic adherence programs.
3. Bioequivalence and Bioavailability Studies: Specialized testing services at Chía location to demonstrate pharmaceutical equivalence between products.
4. Ethics Committee Services: Ethics review and oversight services provided to other research centers and independent investigators.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

CAIMED operates a network of clinical research centers conducting vaccine intervention studies, pharmaceutical studies in chronic diseases, infectious disease research, and bioequivalence/bioavailability studies for pharmaceutical sponsors. It also provides direct vaccination services (PAI and complementary), preventive medicine programs, epidemiological registries, and ethics committee oversight to other research centers.

Product overview

CAIMED is a clinical research center organization offering a comprehensive portfolio of research services and digital health platforms. The core offerings include vaccine intervention studies (primary focus), pharmaceutical studies for chronic diseases, infectious disease research, and bioequivalence/bioavailability studies. These are supported by vaccination services, preventive medicine programs, epidemiological registries, and an Ethics Committee service. The company operates digital platforms including the Patient School (Escuela de Pacientes) for cardiovascular health education, a Preventive Medicine platform for vaccination scheduling, and a Cardiovascular Screening Tool (Termómetro). CAIMED also developed proprietary technology MetricsMed®, an FDA Part 11 compliant electronic data management system. The organization conducts COVID-19 clinical research including vaccine trials and antiviral treatment studies. CAIMED operates across 10 research centers in Colombia, Dominican Republic, Mexico, and the United States.

Differentiator

Problem solved

Functional benefit

Brands

• VITA: CAIMED's main headquarters in Chía, Colombia.
• Preventiva
• Escuela de Pacientes
• Termómetro Cardiovascular

Products and services

• Vaccine Intervention Studies Clinical intervention studies focused on vaccines for adults, pediatrics, and pregnant women, conducted for pharmaceutical sponsors. This is CAIMED's primary research focus area.
• Pharmaceutical Studies for Chronic Diseases Clinical studies in pharmaceutical products for chronic diseases and pre-established conditions, conducted for pharmaceutical sponsors.
• Infectious Disease Studies Studies focused on infectious diseases and special populations, including dengue, COVID-19, and other infectious disease clinical trials.
• Bioequivalence and Bioavailability Studies Studies conducted at the Chía location to demonstrate the relationship between two or more equivalent pharmaceutical products, offered to pharmaceutical sponsors.
• Vaccination Services Direct vaccination services to individuals including PAI (Expanded Program on Immunization) vaccines and complementary vaccines, as well as corporate vaccination programs for employee health.
• Preventive Medicine Programs Preventive medicine and therapeutic adherence programs for individuals and corporate clients seeking proactive health management.
• Epidemiological Registries and Studies Population registries and epidemiological studies to inform public health action and orient health interventions.
• Special Populations Studies Clinical studies focused on special population groups including pediatrics, pregnant women, and other vulnerable populations.
• Ethics Committee in Clinical Research Ethics review and oversight services provided to external research centers and independent investigators for regulatory compliance and protocol approval.
• Professional Training Services Professional development and training services for research teams, providing competency building and continuing education for clinical research professionals.

Quantifiable outcome

• 87+ clinical trials conducted with over 19,000 participants enrolled
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core and minor.

• PanAmerican Clinical ResearchcoreStrategic or Co-development Partner · 15 April 2020Strategic alliance between PanAmerican Clinical Research and CAIMED forming a network of 12 clinical trial sites across Latin America and the US. Includes establishment of a joint research center in Brownsville, TX for Phase I-IV clinical trials. PanAmerican contributes community-oriented patient recruitment and home visit capabilities while CAIMED provides infrastructure and experience in infectious disease and vaccine trials.
• MetricsMedcoreTechnology or IntegrationValidated software platform for clinical research with full FDA Part 11 compliance (Electronic Records and Electronic Signatures). Provides complete digital integration for research operations.
• Corporación SaludminorImplementation/ SI/ Consulting PartnerTraining and education services for research teams, providing professional development and competency building.
• Sanofi PasteurcoreStrategic or Co-development PartnerPhase III COVID-19 vaccine clinical trial conducted at CAIMED sites with over 35,000 volunteers targeted globally across Asia, Africa, Latin America, and North America.
• CureVac AGcoreStrategic or Co-development PartnerPhase IIb/III clinical trial for mRNA COVID-19 vaccine (CVnCoV) with 6,000 Colombian volunteers out of 36,000 total in Europe and Latin America. Supported by Bayer as pharmaceutical partner.

Scale indicators7 records

Recent moves3 records

Broad incumbents

• Parexel: Established global CRO with strong vaccine and infectious-disease franchise, recently taken private. Competes with CAIMED on Phase II/III vaccine and chronic disease trials across the Americas.
• Medpace: Mid-to-large global CRO focused on Phase II/III trials, with growing Latin American presence. Comparable as a contract research organization targeting the same mid-sized pharma sponsors CAIMED serves.
• ICON plc: Global CRO formed via the PRA Health Sciences merger with significant vaccine and infectious-disease trial operations. Competes with CAIMED for Phase IIb/III vaccine and bioequivalence contracts across Latin America and the US.
• Thermo Fisher Scientific (PPD): PPD, the clinical research services arm of Thermo Fisher, is a top-tier global CRO with Phase I-IV vaccine and bioequivalence capabilities. Direct competitor for large pharma vaccine trial contracts that CAIMED also pursues.
• IQVIA: The world's largest CRO with deep Latin American site networks and global vaccine trial capabilities. Comparable as a contract research organization competing for the same pharma sponsors CAIMED serves, though IQVIA operates at vastly greater scale and across all therapeutic areas.
• Worldwide Clinical Trials: Mid-size global CRO with strong vaccine, infectious-disease, and neuroscience expertise. Competes with CAIMED for Phase IIb/III vaccine and chronic disease trial allocations from mid-to-large pharma sponsors.
• Syneos Health: Large global CRO with established Latin American operations and vaccine trial experience. Targets the same pharmaceutical sponsors as CAIMED for multi-region vaccine and chronic disease protocols.
• Charles River Laboratories: CRO with a leading bioequivalence/bioavailability services franchise that directly competes with CAIMED's Chía BE unit. Also provides early-stage clinical and vaccine research services to global pharma.

Regional players

• Hospital Italiano de Buenos Aires (HIBA): Leading Argentine academic medical center with an established clinical research unit. Comparable as a Latin American hospital-based research site competing with CAIMED for multinational vaccine and pharmaceutical protocols.
• Fundación Cardiovascular de Colombia: Colombian clinical research organization and hospital network conducting clinical trials in cardiology and related therapeutic areas. Comparable as a regional Colombian clinical research site competing with CAIMED for local sponsor allocation.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/caimed
• Facebookfacebook.com/Caimed
• LinkedInlinkedin.com/company/caimed
• Instagraminstagram.com/caimedinvestigacion

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centro de Atención e Investigación Médica